United Kingdom

UK adds nerve disorder as rare side-effect of AstraZeneca COVID-19 vaccine

1 minute read
1/2

A medical worker prepares a dose of AstraZeneca COVID-19 vaccine at a vaccination center, amid the coronavirus disease outbreak, in Ronquieres, Belgium April 6, 2021. REUTERS/Yves Herman

Oct 21 (Reuters) - The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca (AZN.L) COVID-19 vaccine, updates on the agency's website showed on Thursday.

Medicines and Healthcare products Regulatory Agency's (MHRA) decision comes after the European medicines agency added GBS as a possible side-effect last month. read more

Register now for FREE unlimited access to reuters.com
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters